Varicella-Zoster Virus-specific adaptive immune response (VZV-specific immunity)

The Varicella-Zoster Virus (VZV)-specific adaptive immune response is a multifaceted defense mechanism comprising both humoral and cell-mediated immunity directed against VZV (StatPearls, 2023). Following primary infection, which causes varicella (chickenpox), the virus remains latent in the cranial nerve and dorsal root ganglia (CDC, 2022). Suppression of this latent virus is primarily mediated by VZV-specific T-cells, particularly CD4+ and CD8+ subsets (PubMed, 2010). A decline in this specific cell-mediated immunity, typically associated with aging or immunosuppression, can lead to viral reactivation, manifesting as herpes zoster (shingles) (StatPearls, 2023). Therapeutic interventions, primarily vaccines, aim to elicit or boost this adaptive response to prevent initial infection or the painful complications of reactivation, such as postherpetic neuralgia (FDA, 2017). Recombinant vaccines like Shingrix utilize viral glycoproteins to specifically stimulate T-cell and antibody production (Journal of Infectious Diseases, 2018). Monitoring this response often involves measuring specific antibody titers or T-cell activity levels to assess protection or vaccine efficacy (PubMed, 2010). This immune response is critical for long-term control of the virus and is a primary focus of geriatric immunology (CDC, 2022).

Other names

VZV-specific T-cell responseVZV-specific humoral immunityVaricella-Zoster Virus immunityVZV-specific cell-mediated immunity

Induction of VZV-specific antibodies and memory T-cells to prevent primary infection or suppress viral reactivation from latency.